ArticleJournal of neurovirology2025
LncRNA MCF2L-AS1 inhibits neuronal damage induced by 1-methyl-4-phenylpyridinium (MPP+) via regulating miR-28-5p.
Article in Journal of neurovirology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second most prevalent progressive neurological movement condition worldwide. Previous studies have reported aberrant expression of lncRNA MCF2L-AS1 in PD. Therefore, this study aims to investigate the clinical significance of MCF2L-AS1 in PD patients and to explore whether MCF2L-AS1 is involved in the disease progression of PD by regulating miR-28-5p expression. The expression of MCF2L-AS1 was detected by using RT-qPCR. The diagnostic function of MCF2L-AS1 in PD was analyzed via ROC curves. CCK-8 assay was used to measure cell viability, and the apoptosis rate and ROS level were detected by flow cytometry. The targeted binding relationship between MCF2L-AS1 and miR-28-5p was detected using a dual-luciferase reporter gene assay. The concentration of MDA, SOD, and proinflammatory factors (TNF-α, IL-1β, and IL-6) was detected by using ELISA kits. This study found that the expression of MCF2L-AS1 was downregulated in patients with PD, and MCF2L-AS1 had predictive potential in PD. In addition, MCF2L-AS1 regulated MPP
Indexed as
Identifiers
41165992What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.